8 results about "Meningococcal carriage" patented technology

The present invention provides fusion proteins having the desire to reduce Factor H binding, in particular the present invention provides optimized processes for the manufacture of fusion proteins and formulations comprising fusion proteins. The present invention provides an effective platform process for the manufacture of an effective vaccine formulation against Neisseria meningitidis, which meets a variety of criteria, including improved immunogenicity, safety, stability, and burdenability.

The present application provides a kind of protecting group B meningococcal infection outer membrane vesicle composition, the outer membrane vesicle composition is by lipopolysaccharide modified group B meningococcal outer membrane vesicle and the outer membrane vesicle of group B meningococcal bacterium expressing recombinant protein is composed.The outer membrane vesicle composition provided by the present application has better protective effect on group B meningococcal infection relative to single strain outer membrane vesicle, and is more suitable for use as vaccine.

The present invention provides a fusion protein in which H factor binding is desiredly reduced, and in particular, the present invention provides an optimized manufacturing process for the fusion protein and formulations containing the fusion protein. The present invention provides an efficient platform process for producing effective vaccine formulations against Neisseria meningitidis that meet multiple criteria with improved immunogenicity, safety, stability and availability.

The invention provides a method for purifying group C meningococcus capsular polysaccharide. The method comprises a rough preparation step and a refining step, wherein in the refining step, two-step elution purification or flow-through combined elution purification is adopted for refining. The refined capsular polysaccharide prepared by the invention meets part of quality standards required by pharmacopeia, and does not use organic solvents and toxic reagents, such as ethanol, phenol, acetone, cetyltrimethylammonium bromide (CTAB) and the like, so that the harm of the capsular polysaccharide to human bodies and the environment is avoided. The method provided by the invention also has the advantages of simple process steps, short process time consumption, reduced production cost, high safety and the like.

This application relates to the technical field of vaccine conjugates, specifically to a method for preparing a polysaccharide conjugate of group A meningococcal capsular polysaccharide, including the preparation of polysaccharide derivatives, mixing ratio, conjugation reaction, aging treatment, ultrafiltration and sterilization steps. This application eliminates the pH adjustment and conjugate purification steps in the activation process by optimizing the process parameters, but the quality of the harvested polysaccharide conjugate still meets the national standards, thereby simplifying the preparation process of polysaccharide conjugates and shortening the preparation cycle of polysaccharide conjugates.

The invention belongs to the field of gene engineering, and particularly discloses a soluble recombinant diphtheria toxin mutant CRM197 protein and a preparation method thereof, and the specific steps are as follows: a codon-optimized diphtheria toxin mutant CRM197 coding sequence is connected to an expression vector pBAD-HisB, and inducible expression is performed in Escherichia coli BW25113; the diphtheria toxin mutant CRM197 is converted into soluble expression from inclusion body by adding a signal peptide sequence at the N terminal, and after fermentation optimization and multi-step purification, the protein purity reaches 95% or above, and the yield is 600 mg / L or above; the invention also provides a fusion protein containing the soluble recombinant diphtheria toxin mutant CRM197 and a group B meningococcus fHBP-V1 or fHBP-V2 fragment, and the fusion protein can be used for developing a group B meningococcus vaccine.

The present invention relates to combination vaccine comprising hexavalent serogroup of Neisseria meningitidis for prevention and prophylaxis of infection caused by meningococcal bacteria. The present invention relates to a hexavalent combination vaccine comprising serogroups A, B, C, Y, W, X of Neisseria meningitidis. The present invention relates to a hexavalent combination vaccine comprising polysaccharide- protein conjugate of serogroups A, C, Y, W, X and proteins of serogroup B of Neisseria meningitidis. The present invention specifically relates to a hexavalent combination vaccine comprising polysaccharide- protein conjugate of serogroup A, C, Y, W, X and mutated Factor H binding proteins (fHbp) of serogroup B of Neisseria meningitidis. The present invention further relates to the composition, use and process of preparation of hexavalent combination vaccine.